Kiora (KPRX) Q2 Revenue Falls 100%

Kiora Pharmaceuticals (NASDAQ:KPRX), a clinical-stage biotech focused on therapies for vision loss and retinal diseases, released its second-quarter results on August 8, 2025. The most notable news was the absence of recognized revenue (GAAP), which came in below the $0.75 million analyst estimate and matched the previous year's $0 result. Net loss was $2.2 million, This was consistent with the prior-year period, with loss per share (GAAP) at ($0.54). Meanwhile, the company made key progress in advancing its two lead clinical programs and secured an option agreement with a major Asian pharmaceutical partner. The quarter highlighted solid operational execution in research and development, with support from non-dilutive partner funding, but cash burn and a reliance on future milestone payments remain noteworthy risks for the business in its current pre-commercial stage. Source: Analyst estimates for the quarter provided by FactSet. Kiora Pharmaceuticals develops medicines for eye diseases that can cause blindness, particularly retinal degenerative diseases where few treatment options exist. Its lead product candidate, KIO-301, is a small molecule “photoswitch” intended to restore light sensitivity in eyes where the photoreceptors have degenerated, such as in retinitis pigmentosa. The company is also advancing KIO-104, an anti-inflammatory small molecule for retinal diseases where inflammation leads to vision loss.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool